1 / 31

Hepatitis A and Hepatitis A Vaccine

Hepatitis A and Hepatitis A Vaccine. Epidemiology and Prevention of Vaccine-Preventable Diseases National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention. Revised March 2008. Note to presenters:

tino
Download Presentation

Hepatitis A and Hepatitis A Vaccine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis A and Hepatitis A Vaccine Epidemiology and Prevention of Vaccine-Preventable Diseases National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Revised March 2008

  2. Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp

  3. Hepatitis A • Epidemic jaundice described by Hippocrates • Differentiated from hepatitis B in 1940s • Serologic tests developed in 1970s • Vaccines licensed in 1995 and 1996

  4. Hepatitis A Virus • Picornavirus (RNA) • Humans are only natural host • Stable at low pH • Inactivated by high temperature (185°F or higher), formalin, chlorine

  5. Hepatitis A Pathogenesis • Entry into mouth • Viral replication in the liver • Virus present in blood and feces 10-12 days after infection • Virus excretion may continue for up to 3 weeks after onset of symptoms

  6. Hepatitis A Clinical Features • Incubation period 28 days (range 15-50 days) • Illness not specific for hepatitis A • Likelihood of symptomatic illness directly related to age • Children generally asymptomatic, adults symptomatic

  7. Hepatitis A Epidemiology • Reservoir Human • Transmission Fecal-oral • Temporal pattern None • Communicability 2 weeks before to 1 week after onset

  8. Hepatitis A—United States, 1990-2000 Risk Factors Source: NNDSS/VHSP

  9. Hepatitis A - United States, 1966-2006 Vaccine Licensed Year

  10. Hepatitis A Incidence By Age Group, 1990-2004 Year

  11. Hepatitis A Incidence By Vaccination Recommendation Status 1990-2004 Year

  12. Hepatitis A Vaccines • Inactivated whole virus • HAVRIX (GlaxoSmithKline) • VAQTA (Merck) • Both vaccines approved for persons 12 months of age and older • Pediatric (12 months through 18 years) and adult (19 years and older) formulations

  13. Hepatitis A Vaccine Immunogenicity • Adults • >95% seropositive after one dose • 100% seropositive after two doses • Children (>12 months) and Adolescents • >97% seropositive after one • 100% seropositive after 2 doses

  14. Hepatitis A Vaccines • Adult • 1 dose • booster dose 6-18 months after first dose • Children and Adolescents • 1 dose • booster dose 6-18 months after first dose

  15. Hepatitis A Vaccine Efficacy • HAVRIX • 40,000 Thai children 1-16 years of age • vaccine efficacy 94% • VAQTA • 1,000 New York children 2-16 years of age • vaccine efficacy 100%

  16. Hepatitis A Vaccines Formulation Pediatric age dose Adult age dose HAVRIX 1-18 yrs 0.5 ml >18 yrs 1.0 ml VAQTA 1-18 yrs 0.5 ml >18 yrs 1.0 ml

  17. ACIP Recommendation for Routine Hepatitis A Vaccination of Children • All children should receive hepatitis A vaccine at 12-23 months of age • Vaccination should be integrated into the routine childhood vaccination schedule • Children who are not vaccinated by 2 years of age can be vaccinated at subsequent visits MMWR 2006;55(No.RR-7):1-23

  18. ACIP Recommendation for Routine Hepatitis A Vaccination of Children • States, counties, and communities with existing hepatitis A vaccination programs for children 2 through 18 years of age should maintain these programs • New efforts focused on routine vaccination of children 12 months of age should enhance, not replace ongoing vaccination programs for older children MMWR 2006;55(No.RR-7):1-23

  19. ACIP Recommendation for Routine Hepatitis A Vaccination of Children • In areas with without an existing hepatitis A vaccination program catch-up vaccination of unvaccinated children 2 through 18 years of age can be considered MMWR 2006;55(No.RR-7):1-23

  20. Hepatitis A Vaccine Recommendations • International travelers • Men who have sex with men • Persons who use illegal drugs • Persons with occupational risk • Persons with chronic liver disease

  21. Hepatitis A VaccineInternational Travel • The first dose of hepatitis A vaccine should be administered as soon as travel is considered • For healthy persons 40 years of age or younger: • 1 dose of single-antigen vaccine administered at any time before departure • Persons at risk of severe disease from hepatitis A virus planning to travel in 2 weeks or sooner should receive the first dose of vaccine and also can be administered immune globulin MMWR 2007;56(No.41):1080-4

  22. Hepatitis A Postexposure Prophylaxis • For healthy persons 12 months through 40 years of age: • single-antigen hepatitis A vaccine should be administered as soon as possible after exposure • For persons older than 40 years: • immune globulin is preferred • vaccine can be used if IG cannot be obtained MMWR 2007;56(No.41):1080-4

  23. Hepatitis A Vaccine Recommendations • Healthcare workers: not routinely recommended • Child care centers: not routinely recommended • Sewer workers or plumbers: not routinely recommended • Food handlers: may be considered based on local circumstances

  24. Twinrix • Combination hepatitis A vaccine (pediatric dose) and hepatitis B (adult dose) • Schedules • 0, 1, 6 months, or • 0, 7, 21- 30 days and a booster dose at 12 months • Approved for persons 18 years of age and older

  25. New Twinrix Schedule • Doses at 0, 7, 21- 30 days and a booster dose at 12 months • ACIP has no recommendation regarding the new schedule • The first 3 doses of the new schedule provide equivalent protection to: • the first dose in the standard single-antigen adult hepatitis A vaccine series • the first 2 doses in the standard adult hepatitis B vaccine series

  26. New Twinrix Schedule • Seroconversion is nearly 100% after either 3 doses of Twinrix on the new schedule or a single dose of single-antigen adult hepatitis A vaccine • No increased benefit of the new schedule for the hepatitis B component compared to administration of 2 hepatitis B vaccine doses 1 to 2 months apart

  27. Schedules That Include BothTwinrix and Hepatitis A Vaccine • Adult formulation single antigen hepatitis A vaccine may be used to complete a schedule begun with Twinrix and vice versa* • Acceptable schedules • 2 Twinrix and 1 hepatitis A (adult formulation • 1 Twinrix and 2 hepatitis A (adult formulation) • Maintain spacing recommended for Twinrix *for persons 19 years of age or older

  28. Hepatitis A Serologic Testing • Prevaccination • not indicated for children • may be considered for some adults and older adolescent • Postvaccination • not indicated

  29. Hepatitis A VaccineAdverse Reactions • Local reaction 20%-50% • Systemic reactions (malaise, fatigue) <10% • No serious adverse reactions reported

  30. Hepatitis A VaccineContraindications and Precautions • Severe allergic reaction to a vaccine component or following a prior dose • Moderate or severe acute illness

  31. CDC Vaccines and ImmunizationContact Information • Telephone 800.CDC.INFO • Email nipinfo@cdc.gov • Website www.cdc.gov/vaccines

More Related